|
VPS25 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.74649994466591E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.55419999781881E-08 |
| Normal-vs-Stage2 |
2.492300E-02 |
| Normal-vs-Stage3 |
9.25569998422304E-09 |
| Normal-vs-Stage4 |
1.78690395813419E-12 |
| Stage1-vs-Stage2 |
1.269370E-01 |
| Stage1-vs-Stage3 |
1.427440E-01 |
| Stage1-vs-Stage4 |
3.67330000000665E-05 |
| Stage2-vs-Stage3 |
1.233840E-02 |
| Stage2-vs-Stage4 |
4.13009999999936E-05 |
| Stage3-vs-Stage4 |
8.659700E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.35409996946134E-09 |
| Normal-vs-AfricanAmerican |
1.78730000000016E-06 |
| Normal-vs-Asian |
7.54080000000545E-05 |
| Caucasian-vs-AfricanAmerican |
3.449400E-01 |
| Caucasian-vs-Asian |
6.491400E-01 |
| AfricanAmerican-vs-Asian |
2.766000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.83320034100143E-10 |
| Normal-vs-Female |
2.54109999708874E-08 |
| Male-vs-Female |
6.129900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.74610000014397E-07 |
| Normal-vs-Age(41-60Yrs) |
1.71420000416589E-08 |
| Normal-vs-Age(61-80Yrs) |
1.38959999951282E-07 |
| Normal-vs-Age(81-100Yrs) |
2.545700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.080800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.882600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.697800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.592000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.550200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.555600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.984700E-03 |
| Classical-VS-Follicular |
1.064390E-01 |
| Classical-VS-Other |
2.231400E-01 |
| Classical-VS-Normal |
3.74050002083237E-09 |
| Tall-VS-Follicular |
1.019850E-03 |
| Tall-VS-Other |
8.694200E-01 |
| Tall-VS-Normal |
3.58630014574146E-10 |
| Follicular-VS-Other |
1.549960E-01 |
| Follicular-VS-Normal |
2.081900E-03 |
| Other-VS-Normal |
2.848400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.65379999998994E-05 |
| Normal-vs-N1 |
2.96229996088471E-09 |
| N0-vs-N1 |
7.562300E-04 |
|
|
